New Pair Recommendations for the Development of High-Sensitivity Troponin I Assays

Published: 24.02.2021

Early diagnosis of acute myocardial infarction (AMI) as a life-threatening disorder is important for immediate evidence-based therapy. The cardiac troponin I (cTnI) is a gold standard and diagnostic cornerstone in the clinical assessment of AMI. It offers accurate and rapid AMI rule outs.

HyTest offers new 2+1 and 2+2 cTnI pair recommendations targeted for cTnI assay development. The pairs can be found under Cat.# RC4T21, Cat.# 4T21cc, Cat.# 4TC2 or Cat.# RC4TC2, and Cat.# 4T27cc.

New Pair recommendations for cTnI assay development:


Our new pair recommendations have high sensitivity, and they correlate well with commercially available cTnI assay (Figure 1) with no cross-reactivity to other cardiac or skeletal isoforms of troponin.

Figure 1. Correlation of HyTest cardiac troponin I in-house assays and commercially available cTnI assay.

Learn more:
4T21/4T21cc Troponin I (cTnI), antibody
RC4T21 Recombinant anti-cardiac troponin I (cTnI), antibody
4TC2 Cardiac troponin complex, antibody
RC4TC2 Recombinant anti-cardiac troponin complex, antibody
4T27cc Troponin C (TnC), antibody

Cardiac Troponins Product Information Page


Sign up to our newsletter

And be informed about new products and scientific findings

Thank you for your subscription!